Lyell Immunopharma
Stock Forecast, Prediction & Price Target
Lyell Immunopharma (LYEL) stock Price Target by analysts
$1
Potential downside: -90.76%
Lyell Immunopharma price prediction
What is Lyell Immunopharma stock analysts` prediction?
Lyell Immunopharma stock forecast: Based on 1 Wall Street analysts` predicted price targets for Lyell Immunopharma in the last 3 months, the avarage price target is $1, with a high forecast of $NaN. The average price target represents a -90.76% change from the last price of $10.83.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Lyell Immunopharma stock Price Target by analysts
Full breakdown of analysts given Lyell Immunopharma price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Geoff Meacham Bank of America Securities | 0% 0/1 | 10 months ago | $1 -90.76% downside | $0.95 | TheFly | Previous targets (0) |
Unknown Morgan Stanley | N/A | almost 3 years ago | $7 -35.36% downside | $4.53 | Benzinga | N/A |
Unknown Goldman Sachs | N/A | over 3 years ago | $12 10.80% upside | $4.01 | Benzinga | N/A |
Lyell Immunopharma Financial Estimates
Lyell Immunopharma Revenue Estimates
Lyell Immunopharma EBITDA Estimates
Lyell Immunopharma Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | ||
Revenue
% change YoY
| $10.65M N/A | $84.68M 695.14% | $130K -99.84% | Avg: $3.33M Low: $3.33M High: $3.33M avg. 2464.1% | Avg: $315.36K Low: $315.36K High: $315.36K avg. -90.53% | ||
Net Income
% change YoY
| $-285.50M N/A | $-4.75M 98.33% | $-234.63M -4835.46% | Avg: $-253.14M Low: $-258.51M High: $-210.82M avg. -7.89% | Avg: $-334.24M Low: $-233.41M High: $-213.33M avg. -32.03% | ||
EBITDA
% change YoY
| $-164.70M N/A | $-165.09M -0.23% | $-226.75M -37.34% | Avg: $-3.33M Low: $-3.33M High: $-3.33M avg. 98.53% | Avg: $-315.36K Low: $-315.36K High: $-315.36K avg. 90.53% | ||
EPS
% change YoY
| -$1.18 N/A | -$0.02 98.37% | -$0.93 -4743.75% | Avg: -$0.91 Low: -$1.03 High: -$0.84 avg. 2.50% | Avg: -$0.89 Low: -$0.93 High: -$0.85 avg. 1.83% | ||
Operating Expenses
% change YoY
| $225.42M N/A | $276.49M 22.65% | $247.13M -10.61% | Avg: $393.75M Low: $393.75M High: $393.75M avg. 59.32% | Avg: $37.25M Low: $37.25M High: $37.25M avg. -90.53% | ||
FAQ
What is Lyell Immunopharma stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -19.96% in 2025-2026.
We have gathered data from 2 analysts. Their low estimate is -258.51M, average is -253.14M and high is -210.82M.
What is Lyell Immunopharma stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 1186.78% in 2025-2026.
We have gathered data from 2 analysts. Their low revenue estimate is $3.33M, average is $3.33M and high is $3.33M.
What is Lyell Immunopharma stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 2.17% in 2025-2026.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$1.03, average is -$0.91 and high is $-0.84.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Lyell Immunopharma stock. The most successful analyst is Geoff Meacham.